Close Menu

SISCAPA Assay Technologies

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.

Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.

Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.

A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.

The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The company plans to offer the immuno-MRM assays as kits covering sample prep and protein digestion as well as immuno-enrichment of specific peptides.

Having gained traction for its technology in the RUO and LDT spaces, the company is now looking to develop its reagents for use in regulatory-cleared IVDs.

NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.